Trending Topic

3d illustration of human body liver
12 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Allan A Lima Pereira, Gabriel Lenz, Tiago Biachi de Castria

Despite being considered a rare type of malignancy, constituting only 3% of all gastrointestinal cancers, the incidence of biliary tract cancers (BTCs) has been increasing worldwide in recent years, with about 20,000 new cases annually only in the USA.1–3 These cancers arise from the biliary epithelium of the small ducts in the periphery of the liver […]

Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 9th 2023

Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the treatment of CML and the use of asciminib and its approval status.

The abstract entitled ‘ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors’ (Abstract #4334) was presented at ASH Annual Meeting, 10–13, December, 2022.

Questions:

  1. What are the limitations of tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia (CML)? (0:20)
  2. What is asciminib and in which CML patients is it indicated? (1:37)

Disclosures: Massimo Breccia has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of ASH 2022

Access more content on Haematological Malignancies and Leukaemia

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup